Sunitinib for metastatic dermatofibrosarcoma protuberans – pro
Dermatofibrosarcoma protuberans (DFSP) is a rare tumor of the dermis layer of the skin, and is classified as a sarcoma. There is only about one case per million per year. There are some case reports, as would be expected for such a rare cancer, that show response to sunitinib. FU reported thelargest series of imatininb failing patients. For 30 patients had Sunitinib treatment after Imatinib failure, 2 had CR (6.7%), 10 had PR (33.3%), 12 had SD (40%) and 6 had PD (20%). The disease control rate (DCR=CR+PR+SD) was 73.3%. The progression free survival (PFS) of CR and PR patients were 22 months and 20 months respectively. The PFS of 12 SD was 18 months, and overall survival (OS) was 28 months. And the median PFS and OS of all 30 patients were 19 and 27 months respectively after Sunitinib treatment.
Fu Y, Kang H, Zhao H, et al. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib. Int J Clin Exp Med. 2015;8(5):8288-8294. Published 2015 May 15.
Xiao W, Que Y, Peng R, et al. A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure. Onco Targets Ther. 2018;11:2439-2443. Published 2018 May 1. doi:10.2147/OTT.S150235